Seattle Genetics Highlights ADCETRIS Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate Collaborator Data at ASCO

Seattle Genetics, Inc. (NASDAQ: SGEN ) today highlighted ongoing clinical development programs for ADCETRIS (brentuximab vedotin) in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress